"It's the first study to show a significant difference between all three covalent BTK inhibitors," says Daniel A. Ermann, MD.

PVR demonstrated superiority versus VR in the ITT analysis population; benefits consistent across prespecified subgroups.

Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 and FLT3 inhibitor, today announced that eleven ...

Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, ...

The treatment landscape of chronic lymphocytic leukaemia has undergone a revolution in the past decade. Highly effective ...

Entered into global collaboration with Roche for bexobrutideg, with potential total payments of up to $2.3 billion, including $700 million ...

The Jaypirca application moves to the EC for a decision, expected within the next one to two months.

The study included 639 patients, 79.8% of whom had previously received covalent BTK inhibitors.

Daniel Ermann, MD, discusses his approach to treatment sequencing in patients with chronic lymphocytic leukemia who aged 80 ...

Chronic lymphocytic leukemia (CLL) treatment options depend on your diagnosis. In earlier stages, “watchful waiting” may be recommended. More advanced CLL may require a combination of therapies.

Chronic lymphocytic leukemia (CLL) is one of the most common types of leukemia in adults and is currently incurable. Dr. Brian Koffman, chief medical officer and executive vice president of the CLL ...

Daniel Ermann, MD, discusses treatment considerations with newly diagnosed older/elderly patients with chronic lymphocytic ...